8-K: Lipella Pharmaceuticals Addresses Nasdaq Delisting, Outlines Path to Relisting and Clinical Progress

Lipella Pharmaceuticals Inc. issued a letter to stockholders addressing its recent Nasdaq delisting, reaffirming operational strength, and detailing plans to relist on a national exchange while advancing its clinical pipeline.

Summary

• Lipella Pharmaceuticals Inc. was delisted from the Nasdaq Capital Market effective June 19, 2025.
• The delisting was due to Nasdaq's determination that certain private placement transactions between December 2024 and March 2025, specifically the issuance of Series C voting convertible preferred stock and warrants as partial compensation, did not comply with Listing Rules 5100, 5635, and 5640, requiring stockholder approval.
• The company's common stock is now quoted on the OTC Pink Market under the symbol LIPO and will be known as OTCID effective July 1, 2025.
• Lipella remains a fully reporting public entity and is committed to full and transparent SEC filings.
• The company is actively exploring relisting options on other national exchanges and intends to submit an initial listing application as soon as possible.
• Clinical operations remain unaffected by the delisting, with core development programs continuing.
• LP-310, for oral lichen planus (OLP), presented statistically significant safety and efficacy data from the first two cohorts of its Phase 2a trial in May 2025, showing strong clinical and patient-reported improvements in pain, ulceration, and disease severity with no systemic exposure and a favorable safety profile.
• Final topline data from the fully enrolled Phase 2a trial of LP-310 is expected in the second half of 2025.
• LP-10, for hemorrhagic cystitis, is continuing development and preparing for additional regulatory interactions.
• The company states it remains operationally sound, maintains prudent fiscal oversight, and is capitalized to support current development programs, emphasizing the delisting was not due to financial distress.

Sentiment

Score: 4

Explanation: The delisting from Nasdaq is a significant negative event impacting liquidity and investor confidence. However, the company's clinical programs are progressing positively, and management is actively pursuing relisting, which mitigates some of the negative sentiment.

Positives

• Clinical operations and development programs (LP-10 and LP-310) remain unaffected by the Nasdaq delisting.
• LP-310, for oral lichen planus (OLP), showed statistically significant safety and efficacy data from its Phase 2a trial in May 2025, demonstrating strong clinical and patient-reported improvements in pain, ulceration, and disease severity with a favorable safety profile and no systemic exposure.
• Both LP-310 and LP-10 target diseases with significant unmet medical needs and commercial potential, with no FDA-approved treatments or late-stage topical therapies for OLP.
• The company maintains in-house chemistry, manufacturing, and controls (CMC) capabilities, providing supply chain flexibility and development speed.
• Lipella Pharmaceuticals remains operationally sound and capitalized to support current development programs, with prudent fiscal oversight.
• The delisting was not related to financial distress or business performance, indicating underlying business strength.
• The company is committed to full and transparent SEC filings and actively pursuing relisting on a national exchange to provide liquidity and investor access.

Negatives

• Lipella Pharmaceuticals Inc. was delisted from the Nasdaq Capital Market effective June 19, 2025.
• The delisting was due to non-compliance with Nasdaq Listing Rules 5100, 5635, and 5640, specifically concerning the issuance of Series C voting convertible preferred stock and warrants as compensation in private placement transactions, which Nasdaq determined required stockholder approval.
• The company's common stock is now traded on the OTC Pink Market, which typically offers less liquidity and investor access compared to a national exchange.

Risks

• Risks related to the company's product candidates (LP-10 and LP-310), including their development, regulatory approval, and commercialization.
• Risks associated with the company's ability to relist its common stock on a national exchange, which is not guaranteed.
• General capital market risks that could affect the company's financial position and operations.
• Uncertainties and assumptions inherent in forward-looking statements, which could cause actual outcomes and results to differ materially from forecasts.

Future Outlook

Lipella Pharmaceuticals is actively exploring options to relist its common stock on a national exchange, intending to submit an initial listing application as soon as possible. The company will continue to advance its clinical programs, LP-310 and LP-10, with final topline data for LP-310's Phase 2a trial expected in the second half of 2025. The company continually evaluates its capital needs and plans to structure any future financings strategically to minimize dilution and support relisting. A reverse stock split may be considered if required for relisting or other stockholder benefits.

Management Comments

• "While we are disappointed with Nasdaq's decision, Lipella's underlying business remains strong."
• "We are advancing meaningful therapies through the clinical program previously outlined, maintaining full SEC compliance, and actively pursuing relisting."
• "Our mission, leadership team, and long-term strategy remain unchanged."
• "We are now focused on forward-looking solutions – specifically, relisting our shares on perhaps another national exchange where we can provide the best liquidity and investor access."
• "Our clinical operations remain unaffected. We are continuing to execute on our core development programs, LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus."
• "Lipella remains operationally sound. We maintain prudent fiscal oversight and continue to fund our key priorities."
• "The delisting was not related to financial distress or business performance. It stemmed from Nasdaq's conclusions based on its review of certain listing rules several months after the transactions closed and finding that placement agent compensation associated with those financings that was made in securities rather than cash did not fully conform to those rules specifications."
• "As with all development-stage biotech companies, we continually evaluate our capital needs based on clinical progress. Any future financings will be structured strategically to minimize dilution and support a national exchange relisting."
• "If required to meet price-based criteria for a national exchange or for other reasons that will be in our stockholders' best interests, a reverse stock split may be considered."

Industry Context

Lipella Pharmaceuticals operates as a clinical-stage biotechnology company focused on reformulating existing generic drugs for new applications, specifically targeting diseases with significant unmet medical needs where approved therapies are lacking. This positions the company within the niche of drug repurposing and development for underserved markets, a common strategy in the biotech sector to de-risk development.

Stakeholder Impact

• Shareholders: Experience reduced liquidity and visibility due to delisting from Nasdaq to OTC Pink. Face potential dilution from future capital raises and the possibility of a reverse stock split. Benefit from continued clinical progress and management's commitment to relisting and transparency.
• Employees: Clinical operations and staffing remain unaffected, suggesting stability in employment related to core R&D activities.
• Customers/Patients: Potential future beneficiaries of LP-10 and LP-310 therapies, as clinical programs are advancing without impact from the delisting.
• Creditors/Suppliers: The company states it remains operationally sound and capitalized, suggesting continued ability to meet obligations.

Next Steps

• Actively exploring relisting options on all national exchanges.
• Intends to submit an initial listing application for relisting as soon as possible.
• Working with legal counsel and advisors to assess the most efficient path forward for relisting.
• Expects to report final topline data from the fully enrolled Phase 2a trial of LP-310 in the second half of 2025.
• Continuing development for LP-10 and preparing for additional regulatory interactions.
• Continually evaluating capital needs and planning strategic future financings.
• May consider a reverse stock split if required for relisting or other stockholder benefits.
• Will continue to issue regular press releases, file all required SEC disclosures, and engage investors directly, including evaluating investor conferences and calls.

Key Dates

Recommendation

Keywords

Lipella Pharmaceuticals, Nasdaq delisting, OTC Pink Market, LIPO, relisting, clinical trials, LP-310, oral lichen planus, LP-10, hemorrhagic cystitis, biotechnology, pharmaceuticals, SEC filing, 8-K, drug development